<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883385</url>
  </required_header>
  <id_info>
    <org_study_id>2021/0016</org_study_id>
    <nct_id>NCT04883385</nct_id>
  </id_info>
  <brief_title>Thromboprophylaxis by Low Molecular Heparin During the Post-partum Period</brief_title>
  <acronym>THROM-PP2021</acronym>
  <official_title>Adherence Between Thromboprophylaxis Prescriptions and Guidelines During the Post-partum Period After the Institution of a Local Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Sud Francilien</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Sud Francilien</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the current level of adequacy of the&#xD;
      thromboprophylaxis prescriptions with the specific institutional protocol during the&#xD;
      post-partum period. The institutional protocol is based on national and international&#xD;
      guidelines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Venous thromboembolism (VTE) became the 4th cause of maternal mortality and the 2nd direct&#xD;
      cause of maternal mortality in France.&#xD;
&#xD;
      The re are only few randomized studies on the thromboprophylaxis during the post-partum&#xD;
      period. This expose some discrepancy between French guidelines, French Society of Anesthesia&#xD;
      &amp; Intensive Care Medecine (SFAR) and National College of French Gynecologists and&#xD;
      Obstetricians (CNGOF ).&#xD;
&#xD;
      The duration and adequate dose of low molecular heparin prescriptions are unclear.&#xD;
&#xD;
      The level of adequacy of thromboprophylaxis prescriptions at Centre Hospitalier Sud&#xD;
      Francilien with the SFAR recommendations appears to be less than 50 % in a preliminary&#xD;
      unpublished study.&#xD;
&#xD;
      Since this assessment, institutional protocol synthesizing thromboprophylaxis guidelines&#xD;
      during the post-partum was exposed and validated among medical staff (both anaesthesiologists&#xD;
      ang obstetricians).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2021</start_date>
  <completion_date type="Anticipated">April 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 8, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Level of adequacy of the thromboprophylaxis prescriptions with the specific institutional protocol during the post-partum period</measure>
    <time_frame>at one year</time_frame>
    <description>Level of adequacy of the thromboprophylaxis prescriptions with the specific institutional protocol during the post-partum period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of adequacy of the thromboprophylaxis prescriptions with the specific institutional protocol after spontaneous or induced vaginal delivery.</measure>
    <time_frame>at one year</time_frame>
    <description>Level of adequacy of the thromboprophylaxis prescriptions with the specific institutional protocol after spontaneous or induced vaginal delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of adequacy of the thromboprophylaxis prescriptions with the specific institutional protocol after a elective or urgent caesar section</measure>
    <time_frame>at one year</time_frame>
    <description>Level of adequacy of the thromboprophylaxis prescriptions with the specific institutional protocol after a elective or urgent caesar section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>causes of non-compliant prescriptions with the institutional protocol.</measure>
    <time_frame>at one year</time_frame>
    <description>Identify the causes of non-compliant prescriptions with the institutional protocol.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Thromboembolic Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical data collection</intervention_name>
    <description>collection of medical data from patients' medical records</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who had given birth at Centre Hospitalier Sud Francilien&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 ages&#xD;
&#xD;
          -  Who had given birth at Centre Hospitalier Sud Francilien&#xD;
&#xD;
          -  Hospitalized during the puerperium at Centre Hospitalier Sud Francilien&#xD;
&#xD;
          -  Being informed of the clinical trial and had offered any opposition for data&#xD;
             collection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Curative treatment of thrombosis by Low molecular-weight or unfractioned heparin&#xD;
             during pregnancy or post-partum period&#xD;
&#xD;
          -  Curative anticoagulant therapy for any cause&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Elsa BROCAS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Sud Francilien</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elsa BROCAS, MD</last_name>
    <phone>(33) 1 61 69 52 30</phone>
    <email>elsa.brocas@chsf.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline TOURTE</last_name>
    <phone>(33) 1 61 69 31 50</phone>
    <email>caroline.tourte@chsf.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Sud Francilien</name>
      <address>
        <city>Corbeil-essonnes Cedex</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa BROCAS, MD</last_name>
      <phone>(33) 1 61 69 52 30</phone>
      <email>elsa.brocas@chsf.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thromboembolic disease</keyword>
  <keyword>Thromboprophylaxis</keyword>
  <keyword>Post-partum period</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>low molecular heparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

